Please ensure Javascript is enabled for purposes of website accessibility

Why Teva Pharmaceutical Industries Shot Higher Today

By Eric Volkman – Sep 28, 2021 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company reached a settlement in a legal dispute with the state of Louisiana.

What happened

On Tuesday, Teva Pharmaceutical Industries (TEVA -0.46%) was one of the few large-cap stocks to rise in price on a terrible day for the stock market. Teva shares closed nearly 4% higher on some positive legal news for the company.

So what

Teva announced that its U.S. affiliate, the similarly named Teva Pharmaceuticals, has agreed to a legal settlement with the state of Louisiana to settle opioid-related claims.

Stethescope and gavel on desk with caduceus ornament and books.

Image source: Getty Images.

These concern Teva's production of such medicines; the state claims that Teva and other opioid makers "engaged in fraudulent marketing regarding the risks and benefits of prescription opioids, which helped fuel Louisiana's opioid epidemic."

Louisiana's suit is one of a host of such legal actions brought by states and other jurisdictions alleging that pharmaceutical companies like Teva contributed to the worsening problem of opioid addiction. Teva has reached settlements with a clutch of those states, but still faces numerous pending lawsuits.

Now what

The Louisiana settlement will see Teva pay $15 million over the course of 18 years to the state. Additionally, it is to donate medicines that it says will "aid in opioid addiction at recovery," contributions it values at $3 million in terms of wholesale acquisition cost.

Teva said the finalization of the settlement is contingent on confirmation from Louisiana by Nov. 2 that all state political subdivisions will essentially accept the arrangement.

Meanwhile, Teva wrote that it "continues to negotiate a national settlement and remains open in parallel to pursuing opportunities with individual states such as the deal announced today, as long as it is consistent with the nationwide approach."

In other instances where that is not a likely possibility -- California and New York were specifically mentioned -- the company will continue to defend its actions and conduct.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Teva Pharmaceutical Industries Stock Quote
Teva Pharmaceutical Industries
TEVA
$8.66 (-0.46%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.